Takeda entered into an agreement with HiFiBiO to research antibody therapies to treat gastrointestinal diseases, cancer and other disorders, PharmaTimes reports.
Here's what you should know:
1. Researchers from both companies will use HiFiBiO's single-cell screening capabilities to search for and develop antibodies.
2. Takeda is paying HiFiBiO upfront, research and development, milestone and royalty payments for the rights to any developed therapy.
3. HiFiBiO President and CEO Liang Schweizer said, "Takeda is a world leader in oncology, gastroenterology and neuroscience therapeutics. This multi-target partnership further validates our ongoing commitment to these types of open-innovation collaborations to better address unmet medical needs around the world."